JCR Pharmaceuticals Co., Ltd. (TYO:4552)
Japan · Delayed Price · Currency is JPY | Market Cap | 63.82B -16.1% |
| Revenue (ttm) | 41.45B +23.7% |
| Net Income | 817.00M |
| EPS | 6.70 |
| Shares Out | 122.03M |
| PE Ratio | 78.09 |
| Forward PE | 217.19 |
| Dividend | 20.00 (3.82%) |
| Ex-Dividend Date | Sep 29, 2026 |
| Volume | 760,500 |
| Open | 535.00 |
| Previous Close | 534.00 |
| Day's Range | 519.00 - 536.00 |
| 52-Week Range | 444.00 - 824.00 |
| Beta | 0.18 |
| Analysts | Buy |
| Price Target | 706.67 (+35.12%) |
| Earnings Date | Oct 29, 2026 |
About JCR Pharmaceuticals
JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, biopharmaceuticals, medical equipment, regenerative medicines, and drug substances in Japan. The comany offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for 4552 stock is "Buy." The 12-month stock price target is ¥707, which is an increase of 35.12% from the latest price.
News
JCR Pharmaceuticals Receives Marketing Authorization in Kuwait for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome
HYOGO, Japan--(BUSINESS WIRE)--JCR announced that IZCARGO, an enzyme replacement therapy indicated for Hunter syndrome, received marketing authorization in Kuwait.
Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for the Development and Potential Commercialization of Novel Investigational Therapy for Hunter Syndrome in the United States, Europe, and Latin America
MILAN & HYOGO, Japan--(BUSINESS WIRE)--Italfarmaco and JCR announced an exclusive license agreement to develop and commercialize JR-141 in the United States, Europe, and Latin America.
JCR Pharmaceuticals Receives Orphan Drug Designation from the Ministry of Health, Labour and Welfare of Japan for Givinostat for Duchenne Muscular Dystrophy
HYOGO, Japan--(BUSINESS WIRE)--The Ministry of Health, Labour and Welfare of Japan granted orphan drug designation to givinostat, an investigational drug for the treatment of DMD.
MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIB
TOKYO & HYOGO, Japan--(BUSINESS WIRE)--JCR and MEDIPAL announced that the first participant has been dosed in the global Phase I/II trial of JR-446 for mucopolysaccharidosis type IIIB.
JCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome
HYOGO, Japan--(BUSINESS WIRE)--JCR announced that IZCARGO, an enzyme replacement therapy indicated for Hunter syndrome, received marketing authorization in the United Arab Emirates.
JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform
HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announ...
JCR Pharmaceuticals' Research Presentations at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders
HYOGO, Japan--(BUSINESS WIRE)--JCR presented new clinical data in a poster session at the 18th International Symposium on MPS and Related Lysosomal Diseases, held June 4-7, 2026.
JCR Pharmaceuticals to Present at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026
HYOGO, Japan--(BUSINESS WIRE)--JCR announced that it will present new clinical data in a poster session at the 18th International Symposium on MPS and Related Lysosomal Diseases.
JCR Pharmaceuticals Presents Preclinical Gene Therapy Data that Demonstrate Promising Central Nervous System Uptake at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
HYOGO, Japan--(BUSINESS WIRE)--JCR announced today that it presented preclinical data from its novel platform technologies in oral and poster sessions at the ASGCT Annual Meeting.
JCR Pharmaceuticals to Present at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
HYOGO, Japan--(BUSINESS WIRE)--JCR will present preclinical data from its novel platform technologies, including JUST-AAV gene therapy, at the ASGCT 29th Annual Meeting this week.
JCR Pharmaceuticals' Research Presentations at WORLDSymposium™ 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders
HYOGO, Japan--(BUSINESS WIRE)--JCR announced the presentation of four datasets demonstrating the potential benefits of its investigational therapies at the WORLDSymposium 2026.
JCR Pharmaceuticals to Present at the 22nd Annual WORLDSymposium™ 2026
HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals announced that it will present data at the 22nd Annual WORLDSymposium 2026, held February 2-6, 2026, in San Diego, Calif.
JCR Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12–15, 2026.
Italfarmaco and JCR Pharmaceuticals Announce Commercialisation Agreement for Givinostat in Japan and Strategic Collaboration in Rare Disease
MILAN & HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals and Italfarmaco announced an exclusive licensing agreement for the development and commercialization of givinostat in Japan.
JCR Pharmaceuticals Enhances Delivery of AAV Gene Therapy to Central Nervous System and Muscle with Novel Capsid Engineering Platform Technology
HYOGO, Japan--(BUSINESS WIRE)--JCR presented non-clinical data that demonstrate the ability of its proprietary JUST-AAV platform to achieve efficient delivery of AAV gene therapy.
JCR Pharmaceuticals Announces Licensing Agreement with Menagen to Commercialize Agalsidase Beta BS I.V. Infusion [JCR] Across Nine MENAT Markets
HYOGO, Japan--(BUSINESS WIRE)--JCR announced an exclusive licensing agreement with Menagen to commercialize Agalsidase Beta BS I.V. Infusion [JCR] across nine MENAT markets.
JCR Pharmaceuticals to Present at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
HYOGO, Japan--(BUSINESS WIRE)--JCR will present non-clinical data from its novel JUST-AAV gene therapy platform technology in an oral session at the ESGCT 32nd Annual Congress.
JCR Pharmaceuticals and Alexion Achieve Milestone in Collaborative Neurodegenerative Disease Program
HYOGO, Japan--(BUSINESS WIRE)--JCR announced that is has achieved a key research milestone in one of its collaborative programs with Alexion, AstraZeneca Rare Disease.
JCR Pharmaceuticals Celebrates its 50th Anniversary of Advancing Science and Changing Lives
HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals today announced that it will celebrate its 50th anniversary on September 13, 2025, marking five decades of advancing science.
JCR Pharmaceuticals Presents Long-Term Clinical Data on Pabinafusp Alfa for the Treatment of Mucopolysaccharidosis Type II (MPS II) at ICIEM 2025
HYOGO, Japan--(BUSINESS WIRE)--JCR announced that it presented new data from its pipeline of brain-penetrant enzyme replacement therapies at the 15th ICIEM 2025.
MEDIPAL HOLDINGS and JCR Pharmaceuticals Sign Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Therapy for GM2 Gangliosidosis
TOKYO & HYOGO, Japan--(BUSINESS WIRE)--JCR and MEDIPAL announced an exclusive global licensing deal and a co-development and commercialization partnership in Japan for JR-479.
JCR Pharmaceuticals to Present at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) 2025
HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals announced that it will present data at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) 2025 next week.
JCR Pharmaceuticals Selected for Japan's Regenerative Medicine CDMO Subsidy Program
HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, has been s...
JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform
HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announ...
JCR Pharmaceuticals Enters License Agreement with Alexion for Proprietary JUST-AAV Capsids to be Used in the Development of Genomic Medicines
HYOGO, Japan--(BUSINESS WIRE)--JCR announced that it has entered into a license agreement with Alexion, for JCR's new, proprietary JUST-AAV capsids to develop genomic medicines.